Head-to-head evidence
Ba253BINEB vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Ba253BINEB
Developed by Boehringer Ingelheim
NCT02182661 · Phase 3 · completed
The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ba253BINEB's landscape · Umeclidinium's landscape